FDA Report Details Emergent BioSolutions Vaccine Violations

BALTIMORE, MD — After the biopharmaceutical company making coronavirus vaccines in Baltimore was investigated by the Food and Drug Administration (FDA), the FDA detailed its findings in a report released Wednesday. Among them are that workers at the Emergent BioSolutions plant in east Baltimore were not trained in quality control and materials were not protected from contaminants.

The facility was ordered to stop making the Johnson & Johnson vaccine pending the FDA investigation.

It was also making the AstraZeneca vaccine for coronavirus, and the plant mixed ingredients for the two last month, prompting the probe, according to The Washington Post, which broke the news of the FDA report’s release.

See the FDA report on Emergent BioSolutions.